Objective Aminoglycosides are critically important antimicrobials used in the treatment of life-threatening infections. A major drawback of usage is hearing loss caused by irreversible damage to the inner ear (ototoxicity). Ototoxicity occurs in ~20% of patients and ~100% of patients with the m.1555A>G mitochondrial DNA mutation. The largest EU patient group exposed to aminoglycosides are children in neonatal intensive care and the effect of hearing loss during infancy is particularly profound as it impedes language acquisition. Thus, there is an urgent need to develop safer aminoglycoside antibiotics. Ototoxicity limits usage despite the antibacterial potency and low incidence of drug resistance provided by this class of antibiotics. Economically, the annual EU cost incurred by drug resistant infections amounts to €1.5 billion, and the cost of hearing impairment is estimated to be €78 billion. Moreover, 25,000 EU patients die annually as a result of infections caused by resistant bacteria and 22.5 million suffer from hearing impairment, with 2 million profoundly deaf. Stanford research recently published in the Journal of Clinical Investigation has shown that it is possible to chemically modify aminoglycosides to diminish ototoxicity while maintaining antibacterial activity. Through a novel collaboration between Stanford and University College London (UCL), the aim of this research is to use a results-guided drug design approach to develop the next generation of safer aminoglycoside antibiotics. For this work, the candidate will have access to 15 novel patented aminoglycoside compounds, crystallography data, murine in vitro and in vitro models of ototoxicity, and a rare biobank of cells from patients with the m.1555A>G mutation. This work will build upon the candidate’s Distinction Masters of Research structural biology experience at Imperial College London, and UCL PhD and recent first-author publication in Human Molecular Genetics related to aminoglycoside ototoxicity. Fields of science medical and health sciencesbasic medicinemedicinal chemistrymedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancenatural sciencesbiological sciencesgeneticsmutationmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticssocial sciencespsychologypsycholinguistics Keywords Deafness hearing loss m.1555A>G aminoglycoside antibiotics ototoxicity drug development Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2015-GF - Marie Skłodowska-Curie Individual Fellowships (IF-GF) Call for proposal H2020-MSCA-IF-2015 See other projects for this call Funding Scheme MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinator UNIVERSITY COLLEGE LONDON Net EU contribution € 251 857,80 Address GOWER STREET WC1E 6BT London United Kingdom See on map Region London Inner London — West Camden and City of London Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 251 857,80 Partners (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all Partner Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement. BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY United States Net EU contribution € 0,00 Address SERRA MALL 450 94305 2004 Stanford See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 160 130,40
